ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1777

Factors Related to Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease

Ichiro Mizushima1, Kazunori Yamada2, Satoshi Hara1, Kiyoaki Ito3, Hiroshi Fujii4 and Mitsuhiro Kawano1, 1Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, 2Department of Advanced Research in Community Medicine,, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 3Kanazawa University Hospital, Kanazawa, Japan, 4Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: IgG4 Related Disease and outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In IgG4-related disease (IgG4-RD), spontaneous, or at least temporary, remissions without treatment have been reported, and watchful waiting may be appropriate in certain patients with asymptomatic and inactive disease. However, the outcomes of patients with IgG4-RD who do not undergo treatment are still unclear. This study aimed to clarify the outcomes of untreated patients with IgG4-RD and the factors related to the outcomes.

Methods: We retrospectively evaluated clinical features including laboratory data and involved organs at diagnosis in 107 patients (pts) with IgG4-RD, who were followed up for more than 6 months, at a single center in Japan. Among them, 27 patients were followed up without treatment after the initial diagnosis. We compared the clinical features of these 27 patients with those of the 80 patients who underwent treatment. The outcomes of untreated patients were investigated, and logistic regression analysis was performed to assess factors related to the outcomes. Deterioration of IgG4-RD was defined as symptomatic, radiological, or functional exacerbation of the organ involved or new organ involvement.

Results: The patients comprised 73 men and 34 women (mean age 65.7 years). The mean follow-up periods were 64.1 (range 7–252) months, and the serum IgG4 levels at diagnosis were 706 (range 10.7–3,610) mg/dL. The 27 untreated patients had significantly lower IgG4-RD responder index (10.8 ± 5.1 vs 13.8 ± 6.8, P=0.048), fewer affected organs (1.9 ± 1.2 vs 3.0 ± 1.6, P=0.001), and lower frequency of ophthalmic and renal parenchymal lesions (25.9% vs 53.8%, P=0.015, and 3.7% vs 26.3%, P=0.012, respectively) than did the 80 patients who underwent treatment. Of these 27 patients, 8 experienced deterioration of IgG4-RD 62.8 (range 3–232) months after the diagnosis. New organ involvement was observed in all 8 patients, 2 of whom concurrently suffered exacerbation of the organs involved. In age- and sex-adjusted logistic regression analysis, serum IgG4 elevation (per 100 mg/dL, odds ratio 1.194, 95% confidence interval 1.017-1.402, P = 0.030) was the only significant factor related to deterioration of disease in untreated patients with IgG4-RD, whereas serum IgG4 levels did not relate to deterioration in patients who underwent treatment (per 100 mg/dL, odds ratio 0.995, 95% confidence interval 0.921-1.075, P = 0.901).

Conclusion: The present study suggests that serum IgG4 levels may be a useful predictor of the outcomes of untreated patients with IgG4-RD, who tend to have fewer affected organs and lower IgG4-RD responder index.


Disclosure: I. Mizushima, None; K. Yamada, None; S. Hara, None; K. Ito, None; H. Fujii, None; M. Kawano, None.

To cite this abstract in AMA style:

Mizushima I, Yamada K, Hara S, Ito K, Fujii H, Kawano M. Factors Related to Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/factors-related-to-deterioration-of-igg4-related-disease-in-untreated-patients-with-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-related-to-deterioration-of-igg4-related-disease-in-untreated-patients-with-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology